Cyclooxygenase 1 (COX-1) is a bifunctional enzyme that exhibits both COX and peroxidase activities.1,2 It is composed of an N-terminal signal peptide, an EGF-like domain, a membrane binding domain, a catalytic domain, and a C-terminal tail.3 COX-1 is constitutively expressed in the gastrointestinal tract, kidney, spleen, liver, and lung and localizes to the endoplasmic reticulum.4,5 The COX component converts arachidonic acid (Item Nos. 90010 | 90010.1 | 10006607) to a hydroperoxyl endoperoxide prostaglandin G2 (PGG2; Item No. 17010) and the peroxidase component reduces the endoperoxide to the corresponding alcohol PGH2 (Item No. 17020), the precursor of PGs, thromboxanes, and prostacyclins.1,2 COX-1 is the target of many non-steroidal anti-inflammatory drugs (NSAIDs) and is responsible for the undesirable gastrointestinal and renal side effects, such as ulcer formation and reductions in the glomerular filtration rate, respectively.6,7 Cayman’s COX-1 Monoclonal FITC Antibody (Clone CX111) is composed of an anti-COX-1 monoclonal antibody conjugated to fluorescein isothiocyanate (FITC; Item No. 33264) and can be used for flow cytometry (FC).WARNING This product is not for human or veterinary use.
